Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Xeris Biopharma Holdings, Inc. ( XERS ) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Earnings Estimates Moving Higher for Rigel ( RIGL ) : Time to Buy?
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stock to Buy for August 8th
RIGL, APG and CLSK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2025.
5 Best Stocks With Relative Price Strength to Buy Right Now
LendingTree, RIGL, and others are standing out with strong relative price strength amid market volatility.
New Strong Buy Stocks for August 8th
INFU, RIGL, TROW, MITSY and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2025.
Rigel Pharmaceuticals ( RIGL ) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Rigel Pharmaceuticals, Inc. ( RIGL ) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel ( RIGL ) Q2 Revenue Jumps 176%
Rigel Pharmaceuticals ( NASDAQ:RIGL ) , a biopharmaceutical company known for developing and selling treatments for cancer and rare blood disorders, released its second quarter 2025 results on August 5, 2025. The most significant takeaway from the earnings release was that GAAP revenue and net ...
Rigel Pharmaceuticals ( RIGL ) Q2 Earnings and Revenues Surpass Estimates
Rigel (RIGL) delivered earnings and revenue surprises of +66.50% and +28.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical ( COLL ) Q2 Earnings Preview: What's in the Cards?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Rigel ( RIGL ) Could Beat Earnings Estimates Again
Rigel (RIGL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Rigel ( RIGL ) Climb 69.55% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 69.6% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing Rigel Pharmaceuticals ( RIGL ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Rigel Pharmaceuticals ( RIGL ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See a 71.97% Upside in Rigel ( RIGL ) : Can the Stock Really Move This High?
The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Rigel ( RIGL ) Is a Great 'Buy the Bottom' Stock Now
Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is Rigel Pharmaceuticals ( RIGL ) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Earnings Estimates Rising for Rigel ( RIGL ) : Will It Gain?
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Rigel ( RIGL ) Could Surge 82.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday - Angi ( NASDAQ:ANGI ) , BorgWarner ( NYSE:BWA )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Rockwell Automation, Inc. ROK rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS and GAAP EPS ...
Rigel Pharmaceuticals ( RIGL ) Beats Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 350% and 22.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
Ardelyx ( ARDX ) Reports Q1 Loss, Misses Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -70% and 8.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Indivior PLC ( INDV ) Q1 Earnings and Revenues Beat Estimates
Indivior (INDV) delivered earnings and revenue surprises of 86.36% and 11.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Rigel ( RIGL ) Upgraded to Buy: What Does It Mean for the Stock?
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday? - SPDR S&P 500 ( ARCA:SPY )
Wall Street digests strong services sector data and weak ADP employment report. Bitcoin is up nearly 5% on the week, as investors look forward to President Trump's White House crypto summit on Friday. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential.
Wall Street Analysts Believe Rigel ( RIGL ) Could Rally 44.93%: Here's is How to Trade
The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.
Rigel Pharmaceuticals ( RIGL ) Surpasses Q4 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday? - SPDR S&P 500 ( ARCA:SPY )
U.S. stocks drop Tuesday as President Donald Trump's tariffs on key trade partners came into effect. The yield on the US 10-year Treasury note falls to 4.13%, its lowest level since October 2024.
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Sea Limited to Post Q4 Earnings: What's in Store for the Stock?
SE's fourth-quarter performance is likely to have benefited from strong Shopee and SeaMoney growth. Competition and FX volatility are expected to have hurt profitability.
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
CORT's Q4 Earnings and Revenues Fall Short of Estimates
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
4 Healthcare Stocks to Buy as the Sector Stages a Comeback
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies.
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.
Will Lower Commercial Premiums Hurt Humana's Q4 Earnings?
HUM's Q4 results are likely to suffer a blow due to escalating operating costs, partly offset by membership growth in the Individual and Group Medicare Advantage business lines.
Does Rigel ( RIGL ) Have the Potential to Rally 40.88% as Wall Street Analysts Expect?
The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.
Wall Street Analysts Predict a 75.79% Upside in Rigel ( RIGL ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 75.8% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Best Momentum Stock to Buy for January 17th
WFC, FHN and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2025.
New Strong Buy Stocks for January 17th
RIGL, PFIS, PBPB, ICL and KMX have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2025.
Rigel ( RIGL ) Upgraded to Buy: Here's Why
Rigel (RIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
